
Bioventus Inc.: updates and filings
Price
$10.46
November 16, 2026Market cap $697M
What Ploutos Investor adds for Bioventus
Part of Ploutos Investor, €9.99 a month
- The full history: 7 fiscal years, from 2019
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- Most of the reported profit is a tax credit, not money earned from customers. We leave out the P/E and the earnings growth, which would not compare with a company that paid tax.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 2, 2026next Feb 5, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
August 2026
May 2026
March 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 13, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Nov 2, 2026Quarterly reportfor the period to Sep 26, 2026Form10-Q
- Nov 2, 2026Results of operationsForm8-K
- Oct 27, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 5, 2026Quarterly reportfor the period to Jun 27, 2026Form10-Q
- Aug 5, 2026Results of operations, other material eventsForm8-K
- Jul 27, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jun 4, 2026Shareholder voteForm8-K
- May 29, 2026Conflict minerals reportFormSD
- May 21, 2026Regulation FD disclosureForm8-K
- May 6, 2026Quarterly reportfor the period to Mar 28, 2026Form10-Q
- May 6, 2026Results of operationsForm8-K
- Apr 22, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 22, 2026Additional annual meeting materialFormDEFA14A
- Apr 22, 2026Annual meeting proxy statementFormDEF 14A
- Mar 5, 2026Shares registered for employeesFormS-8
- Mar 5, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Mar 5, 2026Results of operationsForm8-K
- Feb 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 17, 2025Officer or director changeForm8-K
- Nov 4, 2025Quarterly reportfor the period to Sep 27, 2025Form10-Q
- Nov 4, 2025Results of operationsForm8-K
- Aug 14, 2025Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 6, 2025Quarterly reportfor the period to Jun 28, 2025Form10-Q
- Aug 6, 2025Results of operationsForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 13, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Nov 2, 2026 | 10-Q | Quarterly reportfor the period to Sep 26, 2026 | Document |
| Nov 2, 2026 | 8-K | Results of operations | Document |
| Oct 27, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 5, 2026 | 10-Q | Quarterly reportfor the period to Jun 27, 2026 | Document |
| Aug 5, 2026 | 8-K | Results of operations, other material events | Document |
| Jul 27, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jun 4, 2026 | 8-K | Shareholder vote | Document |
| May 29, 2026 | SD | Conflict minerals report | Document |
| May 21, 2026 | 8-K | Regulation FD disclosure | Document |
| May 6, 2026 | 10-Q | Quarterly reportfor the period to Mar 28, 2026 | Document |
| May 6, 2026 | 8-K | Results of operations | Document |
| Apr 22, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 22, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 22, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Mar 5, 2026 | S-8 | Shares registered for employees | Document |
| Mar 5, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Mar 5, 2026 | 8-K | Results of operations | Document |
| Feb 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 17, 2025 | 8-K | Officer or director change | Document |
| Nov 4, 2025 | 10-Q | Quarterly reportfor the period to Sep 27, 2025 | Document |
| Nov 4, 2025 | 8-K | Results of operations | Document |
| Aug 14, 2025 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 6, 2025 | 10-Q | Quarterly reportfor the period to Jun 28, 2025 | Document |
| Aug 6, 2025 | 8-K | Results of operations | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Apr 19, 2016.
The full analysis
What do Bioventus's filings show?
The filings are where every one of Bioventus's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.